Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2010 - 2026)

Rigel Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $146.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 90.25% year-over-year to $146.7 million; the TTM figure through Mar 2026 stood at $146.7 million (up 90.25% YoY), while the FY2025 annual figure was $155.0 million, up 100.4% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $146.7 million, down from $155.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $155.0 million in Q4 2025, with the low at $49.1 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $77.1 million (2025), against an average of $84.7 million.
• Peak annual rise in Cash & Current Investments reached 173.27% in 2022, while the deepest fall reached 53.42% in 2022.
• Rigel Pharmaceuticals' Cash & Current Investments stood at $58.2 million in 2022, then declined by 2.19% to $56.9 million in 2023, then jumped by 35.81% to $77.3 million in 2024, then soared by 100.4% to $155.0 million in 2025, then dropped by 5.34% to $146.7 million in 2026.
• Business Quant data shows RIGL's Cash & Current Investments at $146.7 million in Q1 2026, $155.0 million in Q4 2025, and $137.1 million in Q3 2025.